Ted M. Ross

Ted M. Ross

Auto-generated profile, based on publicly available information

Ted M. Ross

Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2009 in Respiratory Research
Verified
Journal Article
Open access
PDF file
FTFranklin R Toapanta
Franklin R Toapanta
TRTed M Ross
Ted M Ross
Each year, influenza virus infection causes severe morbidity and mortality, particularly in the most susceptible groups including children, the elderly (>65 years-old) and people with chronic respiratory diseases. Among the several factors that contribute to the increased susceptibility in elderly populations are the higher prevalence of chronic diseases (e.g. diabetes) and the senescence of the immune system.


30 January 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RBRick A. Bright
Rick A. Bright
DCDonald M. Carter
Donald M. Carter
CCCorey J. Crevar
Corey J. Crevar
FTFranklin R. Toapanta
Franklin R. Toapanta
JSJonathan D. Steckbeck
Jonathan D. Steckbeck
TRTed M. Ross
Ted M. Ross
Vaccination is a cost-effective counter-measure to the threat of seasonal or pandemic outbreaks of influenza. To address the need for improved influenza vaccines and alternatives to egg-based manufacturing, we have engineered an influenza virus-like particle (VLP) as a new generation of non-egg or non-mammalian cell culture-based candidate vaccine. We generated from a baculovirus expression system using insect cells, a non-infectious recombinant VLP vaccine from both influenza A H5N1 clade 1 and clade 2 isolates with pandemic potential. VLPs were administered to mice in either a one-dose or two-dose regimen and the immune responses were compared to those induced by recombinant hemagglutinin (rHA). Both humoral and cellular responses were analyzed. Mice vaccinated with VLPs were protected against challenge with lethal reassortant viruses expressing the H5N1 HA and NA, regardless if the H5N1 clade was homologous or heterologous to the vaccine. However, rHA-vaccinated mice showed considerable weight loss and death following challenge with the heterovariant clade virus. Protection against death induced by VLPs was independent of the pre-challenge HAI titer or cell-mediated responses to HA or M1 since vaccinated mice, with low to undetectable cross-clade HAI antibodies or cellular responses to influenza antigens, were still protected from a lethal viral challenge. However, an apparent association rate of antibody binding to HA correlated with protection and was enhanced using VLPs, particularly when delivered intranasally, compared to rHA vaccines. This is the first report describing the use of an H5N1 VLP vaccine created from a clade 2 isolate. The results show that a non-replicating virus-like particle is effective at eliciting a broadened, cross-clade protective immune response to proteins from emerging H5N1 influenza isolates giving rise to a potential pandemic influenza vaccine candidate for humans that can be stockpiled for use in the event of an outbreak of H5N1 influenza.

1 March 2010 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
SRShannan L. Rossi
Shannan L. Rossi
TRTed M. Ross
Ted M. Ross
JEJared D. Evans
Jared D. Evans

23 March 2012 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
BGBrendan M. Giles
Brendan M. Giles
CCCorey J. Crevar
Corey J. Crevar
DCDonald M. Carter
Donald M. Carter
SBStephanie J. Bissel
Stephanie J. Bissel
SSStacey Schultz-Cherry
Stacey Schultz-Cherry
TRTed M. Ross
Ted M. Ross
Highly pathogenic H5N1 avian influenza viruses continue to spread via waterfowl, causing lethal infections in humans. Vaccines can prevent the morbidity and mortality associated with pandemic influenza isolates. Predicting the specific isolate that may emerge from the 10 different H5N1 clades is a tremendous challenge for vaccine design. In this study, we generated a synthetic hemagglutinin (HA) on the basis of a new method, computationally optimized broadly reactive antigen (COBRA), which uses worldwide sequencing and surveillance efforts that are specifically focused on sequences from H5N1 clade 2 human isolates. Cynomolgus macaques vaccinated with COBRA clade 2 HA H5N1 virus-like particles (VLPs) had hemagglutination-inhibition antibody titers that recognized a broader number of representative isolates from divergent clades as compared to nonhuman primates vaccinated with clade 2.2 HA VLPs. Furthermore, all vaccinated animals were protected from A/Whooper Swan/Mongolia/244/2005 (WS/05) clade 2.2 challenge, with no virus detected in the nasal or tracheal washes. However, COBRA VLP–vaccinated nonhuman primates had reduced lung inflammation and pathologic effects as compared to those that received WS/05 VLP vaccines. The COBRA clade 2 HA H5N1 VLP elicits broad humoral immunity against multiple H5N1 isolates from different clades. In addition, the COBRA VLP vaccine is more effective than a homologous vaccine against a highly pathogenic avian influenza virus challenge.

1 March 2010 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
TRTed M. Ross
Ted M. Ross